| | | | |
Article
|
Increased Influence of Genetic Variation on PON1 Activity in Neonates Jia Chen,1,2,3 Madhu Kumar,4 Wendy Chan,2 Gertrud Berkowitz,2 and James G. Wetmur4,5 1The Derald H. Ruttenberg Cancer Center, and Departments
of 2Community and Preventive Medicine, 3Pediatrics,
4Microbiology, and 5Human Genetics, Mount Sinai
School of Medicine, New York, New York, USA Abstract PON1 (paraoxonase-1) detoxifies organophosphates by cleavage of active oxons before they have a chance to inhibit cholinesterases. The corresponding gene PON1 has common polymorphisms in both the promoter (-909, -162, -108) and the coding region (L55M, Q192R) . The five PON1 genotypes were determined for maternal blood (n = 402) and cord blood (n = 229) as part of a study of the effects of organophosphate pesticide exposure on infant growth and neurodevelopment. PON1 enzymatic activities were determined for a majority of subjects. The population contained Caucasians, Caribbean Hispanics, and African Americans. PON1 activity was strongly dependent upon the promoter alleles in both maternal and cord blood. For example, PON1 activities for position -108CC, CT, and TT mothers were 146, 128, and 109 arylesterase U/mL (analysis of variance, p < 0.0001) , whereas the same PON1 activities for the respective cord bloods were 49.0, 32.4, and 23.2 U/mL (p < 0.0001) . Compared with adults, neonates had lower PON1 activity, implying reduced capacity to detoxify organophosphates. In addition there was a larger difference in activity between genotype groups in neonates than in adults. Because the five polymorphisms in PON1 occur in a short stretch of DNA, they were tested for linkage disequilibrium (LD) . Significant LD was found among all three promoter polymorphisms as well as between promoter polymorphisms and L55M, with the strongest LD for Caucasians and the weakest for African Americans. The Caribbean Hispanics fall between these two groups. Surprisingly, significant LD also was observed between the promoter polymorphisms and C311S in PON2. LD between the promoter polymorphisms and Q192R was not significant. |
|
|
|
Address correspondence to J.G. Wetmur, Microbiology,
Box 1124, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New
York, NY 10029-6574 USA. Telephone: (212) 241-7685. Fax: (212) 534-1684.
E-mail: james.wetmur@mssm.edu
This work was supported by grants ES09584 and ES11643
from the National Institute of Environmental Sciences and R827039 from
the U.S. Environmental Protection Agency. J.C. was supported by a Career
Development Award CA81750 from the National Cancer Institute.
The authors declare they have no conflict of interest.
Received 12 November 2002; accepted 7 May 2003. Chlorpyrifos, an insecticide implicated as a developmental neurotoxin in animals
(Shih et al. 1998), has been used routinely in the homes of urban populations
in the United States. The biochemical contributions of metabolizing enzymes
to the neurotoxic potential of chlorpyrifos and other organophosphates remain
subjects of active investigation (Sams et al. 2000; Costa et al. 1999; Furlong
et al. 2000). Specifically, after activation of chlorpyrifos to the reactive
oxon, the oxon may be detoxified by PON1 (paraoxonase-1) before it has the chance
to inactivate acetylcholinesterase in the peripheral nervous system (PNS) and
central nervous system (CNS). PON1, which is associated with high-density lipid
lipoprotein (HDL), also functions to cleave oxidized lipids in low-density lipid
lipoprotein (LDL) as well as in HDL (Aviram et al. 1998, 2000). PON1 also has
an arylesterase activity (Gan et al. 1991). HDL levels and PON1 activities are
somewhat elevated during pregnancy (Roy et al. 1994). As part of the continuing
effort of the Mount Sinai Children's Environmental Health Center to prospectively
assess the neurodevelopmental risks associated with chlorpyrifos exposure in
an inner-city population in New York City, we investigated the genetic determinants
of chlorpyrifos metabolism in a population of ethnically diverse mothers and
their neonates. In this study, we examined the hypothesis that genetic factors
may be more crucial in determining risk in neonates than in adults of various
ethnicities.
The PON1 gene has been fully characterized (Clendenning et al. 1996)
and has been found to be a member of a multigene family of three linked genes,
PON1 (MIM 168820), PON3 (MIM 602720), and PON2 (MIM 602447)
(OMIM 2002), in that order (Primo-Parmo et al. 1996; Entrez Chromosome Map 2002).
Human PON1 had long been recognized to be polymorphic based both on large
differences in serum PON1 activity (Geldmacher-von Mallinckrodt et al. 1983)
and on the phosphodiesterase/arylesterase activity ratio for different substrates,
including organophosphate oxons derived from pesticides and direct-acting cholinesterase
inhibitors such as the nerve gas sarin (Davies et al. 1996). The purified isozymes
retained these differences in organophosphate hydrolysis activity normalized
to arylesterase activity (Smolen et al. 1991). PON1 contains two common
polymorphisms in the coding region, Q192R (Adkins et al. 1993; Humbert et al.
1993) and L55M (Garin et al. 1997), and three common polymorphisms in the promoter
at -909, -162 and -108 (Leviev and James 2000; Brophy et al.
2001a, 2001b). Promoter variants in PON1 affect the level of expression
by more than 2-fold (Boright et al. 1998; Brophy et al. 2001a, 2001b). Q192R
affects the relative rate of hydrolysis of certain organophosphate substrates
compared with phenyl acetate by as much as an order of magnitude but has only
a small effect on chlorpyrifos oxon/phenylacetate rate of hydrolysis (Davies
et al. 1996). The L55M polymorphism has been found to affect lipid peroxidation
(Malin et al. 2001) and PON1 protein stability (Leviev et al. 2001), although
the recent work on promoter mutations has suggested that the apparent effect
of the L55M polymorphism on enzyme concentration also may be due to linkage
disequilibrium (LD) with one of the promoter variants (Brophy et al. 2001b).
Toxicity of chlorpyrifos is inversely related to serum PON1 activity. Intravenous
injection of PON1 before challenge by chlorpyrifos is protective in the rat
(Costa et al. 1990). PON1 knockout mice were more susceptible to chlorpyrifos
toxicity (Shih et al. 1998), and the toxicity was alleviated by intraperitoneal
injection of purified PON1, with the 192RR (homozygous) enzyme providing better
protection than 192QQ (Li et al. 2000). Using the rat model, Attenberry et al.
(1997) have demonstrated that the age-related decrease in susceptibility to
chlorpyrifos CNS toxicity is not due to either the rate of activation to the
oxon or to the reactivity of the oxon in the CNS but is entirely due to age-related
differences in the detoxification of the oxon. Developing human fetuses have
much lower protective PON1 activities than do adults, with the level in cord
blood being severalfold lower (Mueller et al. 1983). Furthermore, both chlorpyrifos
and chlorpyrifos oxon can cross the placenta. Subcutaneous delivery of a high
dose of chlorpyrifos to pregnant rats led to significant (30-49%) inhibition
of fetal acetylcholinesterase activity (Chanda and Pope 1996). Thus, both fetuses
and very young children may be more susceptible to pesticide exposure compared
with adults. Lower PON1 activities may reflect increased risk after acute or
chronic exposure to chlorpyrifos in utero and in the neonatal period.
Using maternal and cord blood, we have carried out a systematic study of the
origin and extent of variation in PON1 activities in our population of three
racial/ethnic groups comprising the majority of many inner-city populations:
Caucasians, African Americans, and Caribbean Hispanics. Specifically, we address
genotype-phenotype relationships for all five polymorphisms and note differences
among these three racial/ethnic groups, highlighting the differences between
mothers and neonates. We also address LD among the five polymorphisms, noting
differences among of three racial/ethnic groups that will affect inference of
haplotypes.
Subjects and Methods
Study Population This study is part of an ongoing prospective study of the effect of pesticide
exposure on infant growth and neurodevelopment conducted at the Mount Sinai
School of Medicine. The study protocol was approved by the institutional review
board. A total of 479 pregnant women scheduled to deliver at Mount Sinai Hospital
and their neonates were enrolled in the study. Seventy-seven of these women
have been excluded because of medical complications, terminations of pregnancy,
very premature births, failure to collect specimens from the women before they
gave birth, delivery of an infant with birth defects, change of residence, or
refusal to continue to participate. A total of 402 maternal blood samples were
obtained from individuals self-identified as being Caucasian (n = 82),
African American (n = 117), or Hispanic (n = 203, predominantly
of Caribbean origin). Maternal blood was collected in heparin-treated Vacutainer
tubes (Becton, Dickinson and Co., Franklin Lakes, NJ) at about 26-30 weeks
of gestation. At birth, a sample of umbilical cord blood was obtained for 229
infants (Caucasian n = 56, African American n = 66, Caribbean
Hispanic n = 107). Cord blood was collected with the same anticoagulant.
Although EDTA is a better anticoagulant for long-term DNA storage and polymerase
chain reaction (PCR), it cannot be used because it inhibits and destabilizes
PON1. Plasma was separated immediately (within 24 hr) by two cycles of centrifugation.
Three aliquots of maternal plasma and three aliquots of cord blood plasma were
frozen at -70°C, one for determination of PON1. The buffy coat was
separated from the red blood cells, and DNA was extracted and purified using
a QIAamp blood kit (Qiagen, Valencia, CA) as described by the manufacturer.
Genotyping All PCR reactions were assembled using standard precautions in an ultraviolet-irradiated
hood in a room dedicated to this purpose to prevent carryover contamination.
The PON1 -909GC,
L55M, and Q192R and the PON2 C311S genotypes were determined by the clamp-dependent
allele-specific PCR (CD-ASPCR) method of Germer and Higuchi (1999). Real-time
PCR methods was selected because it is a single-tube assay and offers high throughput.
The primer sequences for genotyping were as follows:
-909GC:
G (sense), 5´-TGCCTCTGTACAACCATGTC-3´; C (sense), 5´-CGGCGGGGGCGGTGCCTCTGTACAACCATGTG-3´;
reverse, 5´-CATGGAGCAAATCATTCACAG-3´.
L55M: M, 5´-GGCAGAAACTGGCTCTGAAGACA-3´; L, 5´-CGGCGGGGGCGCGGCAGAAACTGGCTCTGAAGACT;
reverse, 5´-CACTCACAGAGCTAATGAAAGCC-3´.
Q192R: Q, 5´-TATTTTCTTGACCCCTACTTACA-3´; R, 5´-CGGCGGGGGCGGGGCTTTCTTGACCCCTACTTACG-3´;
reverse, 5´-CTTCACTTGGACTATAGTAGACAA-3´.
PON2 C311S: S, 5´-CGGCGGCGGCCGCATCCA-3´; C, 5´-TCCGCATCCA-GAACATTCTATG-3´;
reverse, 5´-ACACTGAGGCTACAGAACTTCC-3´.
The -108CT and -162AG genotypes were determined by restriction fragment length polymorphism analysis
of PCR products (Brophy et al. 2001a). For -108CT,
heminested PCR was performed first with the primers 5´-TGGGCGCAGACACCGACGGG-3´ and 5´-GCCCAGCTAGCTGCCGACCC-3´ and after 1,000-fold dilution with
5´-TGGGCGCAGACACCGACGGG-3´ and 5´-CTAGCTGCCGACCCGGCCCAGAGGGG-3´.
The products were digested with BstXI. For -162AG,
the primers were 5´-CCAGGTGCACAGAAGGCG-3´ and 5´-GCTCCTGCGGTGGGGGCTGA-3´,
and the restriction endonuclease was BstUI. For each coded sample, genotypes
were entered into the laboratory database and verified by a second investigator.
PON1 Assay The hydrolysis of phenylacetate to acetic acid and phenol, measured by absorbance
maximum A270, was used to determine human plasma PON1 activity
using the standard definition of units (Furlong et al. 1989). The molar extinction
coefficient of phenol is 1,310. On the order of 5% of the PON1 activity in plasma
may be due to serum cholinesterase and serum albumin (Gan et al. 1991). This
contribution was minimized by performing the assays at high pH. A cholinesterase
inhibitor, in this case eserine sulfate, is also necessary for specificity.
The assay was first performed as described in a Hewlett-Packard diode array
spectrophotometer (Agilent, Palo Alto, CA) equipped with a cell holder equipped
with a thermostat. The assay was then adapted to 96-well format for high throughput
and replication. A buffer solution (1.2)
was prepared as 12 mM Tris-HCl (pH 8.0), 1.2 mM CaCl2, 6 µM
EDTA, and 4.8 µM eserine sulfate. Individual plasma samples were diluted
333-fold by addition of 3 µL plasma per milliliter phosphate-buffered saline.
Phenylacetate was dissolved in water at 36 mM (10)
immediately before use and mixed with nine parts buffer. Two hundred microliters
of this mixture were added to each well. Twenty-microliter aliquots of diluted
plasma were placed in individual wells. The plates were incubated at 37°C
in a Bio-Tek PowerwaveX microplate reader (Bio-Tek, Winooska, VT). The increase
in A270 was followed over time. The slope of the kinetic curve
determined by the instrument software was used to calculate the rate of hydrolysis
of phenylacetate. Blanks included both samples lacking plasma and samples with
plasma but lacking substrate. The measurements of individual samples were reproducible
within 10%, mostly limited by the serum dilution step.
Statistical Analysis The genetic influence of PON1 polymorphisms on PON1 activity was analyzed
by analysis of variance. Because of limited serum availability for enzymatic
activity determinations, a total of 390 maternal and 189 neonate data sets were
analyzed. Log transformation of the enzyme activity was performed to improve
normality. Linear regression was used to assess age-adjusted trends in genotypic
effects on PON1 phenotypes. These relationships were examined separately in
mothers and neonates as well as by race/ethnicity. LD was calculated as D´ based on Lewontin, which ranges from 0 (no LD) to 1 or -1 (complete LD)
(Lewontin 1988). The EH (estimating haplotype-frequency) linkage utility program
(Terwilliger and Ott 1994) was used to determine chi-square statistics and p-values
for tests of allelic association between polymorphic markers. To assess independent
and group effects of polymorphisms on PON1 activity, linear and multivariable
regression models were used to determine the independent and group contributions
of the coding and promoter polymorphisms to phenotypic expression based on Brophy
et al. (2001b). All p-values are two-sided. Statistical tests were performed
using SAS (SAS Institute 2001).
Results
PON Allele Frequencies
Table
1 |
Table
2 |
Table
3 |
Table
4 |
Table
5 |
Single nucleotide polymorphism (SNP) frequencies were obtained for the five
common PON1 polymorphisms and for one common PON2 polymorphism
(Table 1). The promoter alleles are named in the sense direction. Although the
allele frequencies varied substantially among race/ethnicity groups, each of
the six polymorphisms has a minor allele frequency of at least 11% in all of
the ethnic groups.
PON1 Genotypes and PON1 Activity The maternal geometric mean PON1 activity was independent of race/ethnicity,
with mean values of 123, 131, and 130 U/mL for African Americans, Caucasians,
and Caribbean Hispanics, respectively (p = 0.08). Effects of maternal
genotypes and race/ethnicity on maternal PON1 activity are summarized in Table
2. Overall, a statistically significant (p ¾ 0.02) difference in
PON1 activity was found among genotypes of each of the three promoter polymorphisms
as well as L55M. The Q192R polymorphism did not influence PON1 activity with
phenylacetate. When examined by race/ethnicity independently, L55M was not a
significant predictor (p = 0.14) in Caucasian mothers, whereas the promoter
polymorphisms were not significant predictors in African-American mothers (p 0.16). All four polymorphisms remained significant predictors of PON1 activity
in Caribbean-Hispanic mothers (p ¾ 0.05).
For neonates, the geometric mean PON1 activity was dependent on race/ethnicity:
44.4 (referent), 33.3 (p < 0.002), and 25.4 (p < 0.0001)
U/mL for African Americans, Caribbean Hispanics, and Caucasians, respectively.
Effects of neonate genotypes and race/ethnicity on neonate PON1 activity are
summarized in Table 3. Similar to the mothers, the three promoter polymorphisms
as well as L55M (but not Q192R) were significantly associated with PON1 activity
(p < 0.0001). Unlike the mothers, these associations were apparent
in all three race/ethnicity groups (p = 0.02).
Figure 1 compares the genetic influences of the three promoter and L55M polymorphisms
on PON1 activity in mothers and their neonates (all race/ethnicities combined).
There was a striking difference in the PON1 activities, with the neonates having
a geometric mean 4.1-fold lower. In addition, the genetic influence in neonates
appears to be stronger, with no polymorphisms affecting maternal PON1 activity
by more than 35% but with both -108 (and -909) and L55M polymorphisms
affecting PON1 activity by more than 2-fold in neonates.
PON Linkage Disequilibrium: Important Alleles Affecting PON1
Activity Pairwise LD calculations for the five polymorphisms and three race/ethnicities,
reported as D´ and chi-square with associated p-values, are
presented in Table 4. In all three race/ethnicities, the promoter polymorphisms
are in nearly complete LD with one another (D´ 0.9, p < 0.0001). The promoter polymorphisms are also in significant
LD with L55M, but more so for Caucasians than for African Americans. L55M and
Q192R are in LD in Caucasians but not in African Americans. On the other hand,
the promoter polymorphisms -108CT and -909GC are in significant LD with Q192R in African-Americans but not in Caucasians.
Interestingly, strong LD is observed between PON2 C311S and the PON1 promoter polymorphisms in all race/ethnicities, with the strongest linkage in
Caucasians. In all of these cases, values for Caribbean Hispanics fall between
those for Caucasians and African Americans.
Analysis of conditional variance (adjusted for the other polymorphisms based
on Brophy et al. 2001b) showed that maternal -108CT and L55M polymorphisms contributed 12 and 4%, 1 and 9%, and 17 and 12% of the
total variance, respectively, for Caucasians, African Americans, and Caribbean
Hispanics. A similar analysis of conditional variance for neonates showed that
the -108CT and L55M polymorphisms contributed 53 and 44%, 8 and 3%, and 19 and 10% of the
total variance, respectively, for Caucasians, African Americans, and Caribbean
Hispanics.
Table 5 shows the maternal PON1 activities for the nine possible -108CT and L55M genotypes. Using -108CC, 55LL as referent, all three L55M
genotypes of -108TT were significantly different, with decreasing
PON1 activity trend from 55LL (126.6 U/mL) to 55LM (116.1 U/mL) to 55MM (105.1
U/mL). With the same referent, only the -108TT genotype of 55MM
was significantly different, although the sample sizes were low (7 and 9) for
the other -108 genotypes.
Discussion
PON1 Allele Frequencies In this study we have investigated the effect of genotype, as reflected by
all of these five common PON1 polymorphisms, on phenotype, as reflected
by PON1 activity. The subjects were pregnant women and their neonates at risk
of prenatal exposure to chlorpyrifos in the home. The subjects included Caucasians,
African Americans, and Caribbean Hispanics. The observed frequencies (Table
1) for the 192R allele among Caucasians and African Americans were consistent
with previous studies [e.g., 0.28 for Caucasians compared with 0.27-0.31
in several previous studies (Davies et al. 1996; Leviev and James 2000; Brophy
et al. 2001b)]. The allele frequencies for all five PON1 SNPs and for
PON2 S311C among Caribbean Hispanics in New York City fell between the
values for Caucasians and African Americans, with allele frequencies consistent
with similar Caucasian and African-American derivation. This study was the first
to include all of these polymorphisms and these race/ethnicities in a study
of PON1 activity in mothers and their neonates.
PON1 Genotypes and PON1 Activity: Increased Genotypic Influence
in Neonates
Figure 1. PON1 activity by genotype,
all race/ethnicities combined for mothers and neonates. Normal refers to
the allele with the highest PON1 activity. Genotypes: (A) –909GÆC;
(B) –162AÆG; (C) –108CÆT; (D) L55M. (A, C, D) Maternal
and neonate p-value for trend < 0.0001. (B) Maternal p-value for trend
= 0.02; neonate p-value for trend < 0.0001. |
It has been known for many years that neonates have much lower PON1 activities
than adults (Mueller et al. 1983). We have confirmed this observation for each
of the race/ethnicities (Tables 2 and 3, Figure 1). Specifically, the mean PON1
activity in maternal blood was 4.6, 3.6, and 2.6 times greater than the mean
PON1 activity in cord blood for Caucasians, Caribbean Hispanics, and African
Americans, respectively. Again, the data for Caribbean Hispanics fall between
Caucasians and African Americans. For all groups, however, the results suggest
a potentially greater degree of susceptibility of a fetus or newborn to the
toxic effects of organophosphates.
Effects of functional polymorphisms in the coding region of a gene (e.g.,
L55M and Q192R) normally remain constant throughout the life of an individual.
Polymorphisms in the promoter region of a gene (e.g., -909, -168,
-108) can affect the level of transcription. We hypothesized that transcription
factor interactions with the promoter may vary throughout life. PON1 activity
differed among genotypes for promoter polymorphisms, as exemplified by -108CT,
and the functional polymorphism L55M. A significant effect of Q192R on PON1
activity was found in one large recent study (Brophy et al. 2001b). Our results
for all race/ethnicities individually as well as combined agree with a second
recent study showing no significant effect (Leviev and James 2000), but this
lack of effect may be due to smaller sample size. In our combined maternal population,
the -108CC and -108TT homozygotes as well as the 55LL
and 55MM homozygotes had approximately 15% greater and lesser activities than
the corresponding heterozygotes, respectively. The effect of the promoter polymorphisms
in African-American mothers did not reach the level of significance, probably
because of sample size considering the lower minor allele frequency. Another
study found 20 and 12% for the -108 and L55M polymorphisms, respectively
(Leviev and James 2000), and a third study found about 27 and 20%, respectively
(Brophy et al. 2001b). All of these results are similar and are strikingly different
from our results with cord blood.
In particular, in our combined neonate population, the -108CC and -108TT homozygotes as well as the 55LL and 55MM homozygotes
had approximately 51 and 40% greater and 28 and 47% lesser activities than the
corresponding heterozygotes, respectively. Thus, not only is the average potential
risk to a fetus or newborn from organophosphate exposure greater than in the
adult, the range of protection afforded by PON1 is more dependent on genotype
than in the adult, with the -108TT and the 55MM homozygotes having
PON1 activities 5.8- and 7.8-fold lower than the average adult, respectively.
PON Linkage Disequilibrium: Important Alleles Affecting PON1
Activity As previously observed (Leviev and James 2000; Brophy et al. 2001b), the promoter
polymorphisms were in significant LD (Table 4). Examination of maternal PON1
activity and genotypes confirmed that nearly all of the contribution of these
polymorphisms to PON1 activity could be determined by analyzing the -108
polymorphism.
The LD extends to L55M and -108CT,
but is less than among the promoter polymorphisms, with D´ varying
from 0.42 to 0.51 depending on race/ethnicity. After correction for LD, Leviev
and James (2000) and Brophy et al. (2001b) found that the -108CT polymorphism accounted for 24.7 and 22.8%, respectively, of the variance in
PON1 for Caucasians. They also found that L55M accounted for 4.4-4.6 or
4.1% of the variance, respectively. Our data for Caucasian mothers were qualitatively
consistent, with conditional variances attributable to -108CT being greater than that attributable to L55M, at 12 and 4%, respectively, after
adjustment for the other polymorphisms. In Table 5, PON1 activity for all three
L55M genotypes combined with -108TT were significantly different
from the referent (55LL, -108CC, p < 0.02) and decreased
from 126.6 (55LL) to 116.1 (55ML) to 105.1 (55MM) U/mL. Although the number
of neonates was smaller than the number of mothers, the conditional variance
attributable to genes was greater, and both polymorphisms again contributed
significantly. Taken together, these data suggest that analysis of both -108CT and L55M PON1 genotypes is required to infer phenotype from genotype.
LD for Q192R depended strongly on race/ethnicity, with D´ to -108CT being -0.93 (p < 0.0001) in Caucasians and -0.18 (not significant)
in African Americans. The reverse was seen for L55M and Q192R, with D´ being -0.43 (p < 0.01) in African Americans and 0.16 (not significant)
in Caucasians. As expected, D´ values for Caribbean Hispanics fell
between those for Caucasians and African Americans. Although Q192R had no significant
effect on PON1 activity as measured using phenyl acetate as the substrate, this
polymorphism affects substrate specificity and thus affects the enzymatic activity
with other substrates, such as chlorpyrifos oxon, both in vitro and in
vivo (Furlong et al. 2000). Therefore, for other substrates, Q192R genotype
must also be determined to infer phenotype from genotype, and the race/ethnicity
dependence of LD must be taken into account.
Linkage disequilibrium depends on local recombination rate (Taillon-Miller
et al. 2000), population structure, and the number of generations since the
mutation (polymorphism) arose (Slatkin 1999). There has been a significant debate
over the size of the DNA blocks exhibiting LD (Reich et al. 2001; Dunning et
al. 2000; Abecasis et al. 2001). In this study we also looked at LD between
the PON1 polymorphisms and PON2 C311S located 97.2 kb away from
Q192R and more distant from the other PON1 polymorphisms. PON2 C311S exhibits significant LD only in Caucasians for PON1 L55M (D´ = -0.43, p < 0.05) and no linkage for PON1 Q192R. However,
PON2 C311S was highly linked to PON1 -108CT in all three race/ethnicities. It is of interest to note that both PON1 (Imai et al. 2000) and PON2 (Sanghera et al. 1998) polymorphisms have
been linked to cardiovascular disease, although a mechanism for PON2 action
has not been demonstrated (Mackness et al. 1999). The LD demonstrated in this
work may facilitate similar epidemiologic analyses.
|
|
|
References Abecasis GR, Noguchi E, Heinzmann A, Traherne JA, Bhattacharyya
S, Leaves NI, et al. 2001. Extent and distribution of linkage disequilibrium
in three genomic regions. Am J Hum Genet 68:191-197.
Adkins S, Gan KN, Mody M, La Du BN. 1993. Molecular basis for
the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or
arginine at position 191, for the respective A or B allozymes. Am J Hum Genet
52:598-608.
Atterberry TT, Burnett WT, Chambers JE. 1997. Age-related differences
in parathion and chlorpyrifos toxicity in male rats: target and nontarget esterase
sensitivity and cytochrome P450-mediated metabolism. Toxicol Appl Pharmacol
147:411-418.
Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et
al. 2000. Human serum paraoxonases (PON1) Q and R selectively decrease lipid
peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase
and peroxidase-like activities. Circulation 101:2510-2517.
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo
SL, La Du BN. 1998. Paraoxonase inhibits high-density lipoprotein oxidation
and preserves its functions. A possible peroxidative role for paraoxonase. J
Clin Invest 101:1581-1590.
Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele
RA. 1998. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated
with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis
139:131-136.
Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik
GP, Furlong CE. 2001a. Polymorphisms in the human paraoxonase (PON1) promoter.
Pharmacogenetics 11:77-84.
Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik
GP, Furlong CE. 2001b. Effects of 5´ regulatory-region polymorphisms on
paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436.
Chanda SM, Pope CN. 1996. Neurochemical and neurobehavioral
effects of repeated gestational exposure to chlorpyrifos in maternal and developing
rats. Pharmacol Biochem Behav 53:771-776.
Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong
CE. 1996. Structural organization of the human PON1 gene. Genomics 35:586-589.
Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE.
1999. The role of paraoxonase (PON1) in the detoxication of organophosphates
and its human polymorphism. Chem-Biol Interact 119-120:429-438.
Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky
AG, et al. 1990. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon
toxicity in rats. Toxicol Appl Pharmacol 103:66-76.
Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J,
Furlong CE. 1996. The effect of the human serum paraoxonase polymorphism is
reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
Dunning AM, Durocher F, Healey CS, Teare MD, McBride SE, Carlomagno
F, et al. 2000. The extent of linkage disequilibrium in four populations with
distinct demographic histories. Am J Hum Genet 67:1544-1554.
Entrez Chromosome Map. 2002. Available: http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?,
expanded to see PON1, PON3, PON2 [accessed 5 November 2002].
Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E,
et al. 2000. Genetic and temporal determinants of pesticide sensitivity: role
of paraoxonase (PON1). Neurotoxicology 21:91-100.
Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. 1989.
Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites
of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem
180:242-247.
Gan KN, Smolen A, Eckerson HW, La Du BN. 1991. Purification
of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing
both activities. Drug Metab Dispos 19:100-106. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel
P, et al. 1997. Paraoxonase polymorphism Met-Leu54 is associated with modified
serum concentrations of the enzyme. A possible link between the paraoxonase
gene and increased risk of cardiovascular disease in diabetes. J Clin Invest
99:62-66.
Geldmacher-von Mallinckrodt M, Diepgen TL, Duhme C, Hommel
G. 1983. A study of the polymorphism and ethnic distribution differences of
human serum paraoxonase. Am J Phys Anthropol 62:235-241.
Germer S, Higuchi R. 1999. Single-tube genotyping without oligonucleotide
probes. Genome Res 9:72-78.
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ,
Furlong CE. 1993. The molecular basis of the human serum paraoxonase activity
polymorphism. Nat Genet 3:73-76.
Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A,
et al. 2000. Evidence for association between paraoxonase gene polymorphisms
and atherosclerotic diseases. Atherosclerosis 149:435-442.
Leviev I, Deakin S, James RW. 2001. Decreased stability of
the M54 isoform of paraoxonase as a contributory factor to variations in human
serum paraoxonase concentrations. J Lipid Res 42:528-535.
Leviev I, James RW. 2000. Promoter polymorphisms of human paraoxonase
PON1 gene and serum paraoxonase activities and concentrations. Arterioscler
Thromb Vasc Biol 20:516-521.
Lewontin RC. 1988. On measures of gametic disequilibrium. Genetics
120:849-852.
Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et
al. 2000. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying
organophosphorus compounds. Pharmacogenetics 10:767-779.
Mackness B, Durrington PN, Mackness MI. 1999. Polymorphisms
of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet
353:468-469.
Malin R, Laine S, Rantalaiho V, Wirta O, Pasternack A, Jokela
H, et al. 2001. Lipid peroxidation is increased in paraoxonase L55 homozygotes
compared with M-allele carriers. Free Radic Res 34:477-484.
Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER,
Motulsky AG. 1983. Plasma paraoxonase polymorphism: a new enzyme assay, population,
family, biochemical, and linkage studies. Am J Hum Genet 35:393-408.
OMIM. 2002. Online Mendelian Inheritance in Man. Available:
http://www.ncbi.nlm.nih.gov/Omim/ (for PON1 [MIM 168820], PON2 [MIM 602447],
PON3 [MIM 602720]) [accessed 5 November 2002].
Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996. The
human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene
family. Genomics 33:498-507.
Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter
DJ, et al. 2001. Linkage disequilibrium in the human genome. Nature 411:199-204.
Roy AC, Loke DF, Saha N, Viegas OA, Tay JS, Ratnam SS. 1994.
Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in
normal pregnancy. A longitudinal study. Gynecol Obstet Invest 38:10-13.
Sams C, Mason HJ, Rawbone R. 2000. Evidence for the activation
of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver
microsomes. Toxicol Lett 116:217-221.
Sanghera DK, Aston CE, Saha N, Kamboh MI. 1998. DNA polymorphisms
in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary
heart disease. Am J Hum Genet 62:36-44.
SAS Institute. 2001. SAS/STAT Guide for Personal Computers,
Version 8. Cary, NC:SAS Institute, Inc.
Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. 1998.
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and
atherosclerosis. Nature 394:284-287.
Slatkin M. 1999. Disequilibrium mapping of a quantitative-trait
locus in an expanding population. Am J Hum Genet 64:1764-1772.
Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. 1991. Characteristics
of the genetically determined allozymic forms of human serum paraoxonase/arylesterase.
Drug Metab Dispos 19:107-112.
Taillon-Miller P, Bauer-Sardina I, Saccone NL, Putzel J, Laitinen
T, Cao A, et al. 2000. Juxtaposed regions of extensive and minimal linkage disequilibrium
in human Xq25 and Xq28. Nat Genet 25:324-328.
Terwilliger J, Ott J. 1994. Handbook of Human Genetic Linkage.
Baltimore, MD:Johns Hopkins University Press.
Last Updated: August 5, 2003 |
|
|
|
| |